Barinthus Biotherapeutics (NASDAQ:BRNS) Shares Down 15.5% – Here’s Why

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) traded down 15.5% on Tuesday . The stock traded as low as $1.06 and last traded at $1.25. 832,679 shares traded hands during mid-day trading, an increase of 432% from the average session volume of 156,556 shares. The stock had previously closed at $1.48.

Barinthus Biotherapeutics Stock Down 15.5%

The company has a market cap of $50.90 million, a price-to-earnings ratio of -0.72 and a beta of -0.75. The company has a fifty day simple moving average of $1.26 and a two-hundred day simple moving average of $1.05.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23). On average, research analysts predict that Barinthus Biotherapeutics PLC Sponsored ADR will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC purchased a new position in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned 0.09% of Barinthus Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 25.20% of the company’s stock.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.